API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
AIT-101 (apilimod dimesylate) is a first-in-class, potent and highly selective inhibitor of the lipid kinase PIKfyve. It is being developed for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Apilimod mesylate
Therapeutic Area: Neurology Product Name: AIT-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
AIT-101 (apilimod dimesylate) is a potent and highly selective inhibitor of the lipid kinase PIKfyve, which activates the transcription factor TFEB which drives the increased clearance of toxic protein aggregates. It is being investegated for treating C9ORF72 ALS.
Lead Product(s): Apilimod mesylate
Therapeutic Area: Neurology Product Name: AIT-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
The randomized, double-blind, placebo-controlled study will enroll up to 142 outpatients to evaluate the safety, tolerability, and efficacy of LAM-002A in reducing viral load in subjects with a confirmed COVID-19.
Lead Product(s): Apilimod mesylate
Therapeutic Area: Infections and Infectious Diseases Product Name: LAM-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
Company receives FDA guidance for pivotal trial design in follicular lymphoma to support accelerated and full approval.
Lead Product(s): Apilimod mesylate,Rituximab,Atezolizumab
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2020